Cellular Origins: Geoffrey Hodge

Geoffrey Hodge

Melbourn, Cambridgeshire-based Cellular Origins, a TTP company focused on enabling manufacture of cell and gene therapies, has appointed Geoffrey Hodge as a non-executive director.

Hodge has experience in cell therapy and biomanufacturing. He was most recently chief executive of Sotio Biotech US and chief technology officer of Unum Therapeutics, both autologous cell therapy companies. Prior to working in the cell therapy sector, Hodge co-founded Xcellerex, where he was the primary inventor of the XDR single-use bioreactor and head of the contract development and manufacturing organisation biomanufacturing services business, which helped the company grow to $50 million in revenue prior to its acquisition by GE Healthcare.

Dr Edwin Stone, chief executive at Cellular Origins, said: “Geoff has unique experience having built businesses that have transformed bioprocess manufacturing. There are very few individuals who have been through this journey. At Cellular Origins, we know how important it is to our customers that we can deliver solutions they can rely on and trust for the manufacturing of important therapies. Geoff’s expertise in building a business that was successful in doing this will be invaluable to Cellular Origins. His guidance, technical and commercial insight and industry network are, and will continue to be, a crucial asset as we realise our ambition to achieve faster, cost-effective and efficient routes to scalable manufacture of cell therapies.”

Hodge commented: “Cellular Origins offers a transformative, industry-ready solution that addresses the challenges of manufacturing cell therapies at scale. I look forward to joining the board and further deepening my involvement in the company at this exciting time in its development and growth.”

Join our mailing list

Stay up to date with all our events, awards and publications.

Information you provide us with will be kept private at all times, and will be used for communication and research purpose only.